secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTENSITY THERAPEUTICS, INC. (INTS)
CIK:        0001567264
Form:       8-K
Filed at:   2026-03-27T23:59:59+00:00
Accession:  0001567264-26-000025
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intensity Therapeutics 2025 net loss $11.6M; cash $11.9M; TNBC trial pCR 71% vs 33%
--------------------------------------------------------------------------------

- Net loss narrowed to $11.6M from $16.3M in 2024; R&D spend fell to $6.8M from $10.5M.
- Cash and equivalents $11.9M at Dec 31, 2025; raised >$20M in 2025; runway into Q2 2027.
- INVINCIBLE-4 TNBC trial: 5/7 (71.4%) pCR with INT230-6+SOC vs 2/6 (33%) SOC alone; fewer grade 3+ AEs.
- INVINCIBLE-3 sarcoma trial paused in March 2025; 21 patients enrolled; restart depends on funding.
- IT-01 study published in eBioMedicine: 75% disease control rate, median OS 11.9 months in refractory tumors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1567264/000156726426000025/0001567264-26-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1567264/000156726426000025/intensity-20260327.htm
  HTML page:      https://secwatch.observer/filing/0001567264-26-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer